Prof Wolfson Institute of Population Health, QMUL; Consultant Gynae-Oncologist Barts Health NHS Trust; Hon Prof LSHTM; Precision Prevention in Women’s Cancers
- Tweets861
- Following480
- Followers1.1K
- Likes3.2K
ALT At the top of the graphic is the following logo: "OCRA 16th BIENNIAL RIVKIN OVARIAN CANCER RESEARCH SYMPOSIUM. October 16 - 18, 2026. Philadelphia, PA." Underneath are images of Barbara Norquist, MD, and Ranjit Manchanda, MD, MRCOG, PhD. Text at bottom of graphic reads: "Prevention & Early Detection: Barbara Norquist, MD, and Ranjit Manchanda, MD, MRCOG, PhD."
ALT PROTECT-C is a research study offering genetic testing to identify people with inherited changes that increase the risk of breast, ovarian, bowel, or womb cancer, regardless of personal or family history. These cancers make up half of all cancers in women, and a proportion are linked to cancer genes that can be managed through NHS screening or preventive options. Current NHS testing criteria miss many people with genetic changes, meaning most remain unaware of their risk. The study will offer testing to 5000 people for nine cancer genes and provide personalised breast and ovarian cancer risk estimates using the CANRISK algorithm. It will assess how many people choose testing, how many genetic changes are found, how many would be missed by standard criteria, and how women respond to personalised risk information. The study will also evaluate user experiences, decision making, uptake of screening or prevention, and NHS affordability.
